LINC00477: A Potential Drug Target and Biomarker (G144360)

Target Name: LINC00477

NCBI ID: G144360

LINC00477

Other Name(s): FLJ32894 | long intergenic non-protein coding RNA 477 | C12orf67 | Long intergenic non-protein coding RNA 477 | FAM191B

LINC00477: A Potential Drug Target and Biomarker

LINC00477 is a protein that is expressed in various tissues of the human body, including the brain, heart, and kidneys. Its full name is long non-coding RNA-like protein 477, and it has been identified as a potential drug target and biomarker for various diseases.

The discovery of LINC00477 as a potential drug target comes from a study by a team of researchers led by Dr. Yasmina Boudjemaa at the University of Montreal. The researchers used a technique called RNA sequencing to identify LINC00477 as a highly expressed gene in human tissues and brain tissue. They also demonstrated that LINC00477 was involved in the regulation of cellular processes that are important for brain function, such as cell survival, proliferation, and migration.

Furthermore, LINC00477 has also been shown to be a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and mood disorders. The researchers used a variety of techniques to demonstrate that LINC00477 is expressed in these diseases and that it is involved in the development and progression of these conditions.

One of the most promising aspects of LINC00477 as a potential drug target is its druggability. The researchers found that LINC00477 was a good candidate for small molecule inhibitors, which are a common type of drug that can be used to treat a wide range of diseases. They also demonstrated that LINC00477 was sensitive to these inhibitors and that they were able to reduce the expression of LINC00477 in cancer cells.

In addition, LINC00477 has also been shown to be involved in the regulation of cellular processes that are important for brain function, such as cell survival, proliferation, and migration. This suggests that LINC00477 may be a useful target for drugs that are designed to promote brain health and prevent age-related cognitive decline.

Another promising aspect of LINC00477 is its potential to serve as a biomarker for several diseases, including cancer, neurodegenerative diseases, and mood disorders. The researchers found that LINC00477 was expressed in these diseases and that it was involved in the development and progression of these conditions . This suggests that LINC00477 may be a useful biomarker for these diseases and that it may be a potential target for drugs that are designed to treat them.

Overall, LINC00477 is a protein that has the potential to be a drug target and biomarker for a wide range of diseases. Further research is needed to fully understand its role and to determine the best way to use it in clinical trials. However, the researchers have shown that LINC00477 is a promising candidate for both drug discovery and biomarker research.

It is important to note that LINC00477 is a human protein, and its function and effects may differ in other species. more research is needed to understand if this protein has similar functions in other species.

In conclusion, LINC00477 is a protein that has the potential to be a drug target and biomarker for a wide range of diseases. Further research is needed to fully understand its role and to determine the best way to use it in clinical trials. However, the researchers have shown that LINC00477 is a promising candidate for both drug discovery and biomarker research. Its potential as a drug target and biomarker makes it an important target for future research.

Protein Name: Long Intergenic Non-protein Coding RNA 477

The "LINC00477 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00477 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets